SEATTLE - Atossa Therapeutics, Inc. (NASDAQ:ATOS), a biopharmaceutical company focusing on breast cancer treatment with a market capitalization of $107 million, has encountered a challenge in its ...

Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, and will now pause its development.

Ypsilon Therapeutics, a portfolio company of 82VS, Alloy’s venture studio, has been awarded $2.7 million in seed funding from ...